Europe Cancer Tissue Diagnostics Market

Cancer Tissue Diagnostics market in Europe is expected to grow from US$ 512.73 Mn in the year 2018 and is expected to reach US$ 830.28 Mn by 2027 growing at a CAGR of 5.8% over the forecast period.

The growth of the market is driven by the factors such as increasing number of cancer cases and rising geriatric population. On the other hand, high cost of cancer diagnostics in some of the European countries is limiting the growth of market is likely to have a negative impact on the growth of the market in the coming years.

Cancer is among the leading cause of deaths across Europe globe and is profoundly affecting the quality of life. Thus, cancer will be a burden on society if not diagnosed and treated on time. According to the World Health Organization in 2018, approximately 9.6 million deaths across the globe were due to cancer. Additionally, cancer is found to be commonly prevalent in European countries as well. As per the Cancer Research UK, in 2016, around 163,444 deaths in the UK were due to cancer.

The World Health Organization (WHO) also reported that with over 3.7 million new cases and 1.9 million deaths each year, cancer is the second most important cause of morbidity and death in Europe. Moreover, Europe comprises of one-eighth of the total world population, however approximately a quarter of global cancer cases with 3.7 million new patients are from Europe, suggesting high incidence rate of cancer in the region. Furthermore, the data also suggests that 40% of these cancer cases are preventable with appropriate diagnosis at early stages and correct treatment and medication.

The Spain Cancer Tissue Diagnostics market is expected to grow at highest rate during the forecast period owing to various cancer research studies undergoing in the country, increasing number of cancer patients in the country, and various solutions undertaken to reduce the financial burden due to cancer on the country. Moreover, the country also is the fastest growing among other European countries owing to the increasing medical tourism flourishing in Spain.

Spain Cancer Tissue Diagnostics Market Revenue and Forecasts to 2027 (US$ Mn)

Europe Cancer Tissue Diagnostics Strategic Insights

Strategic insights for the Europe Cancer Tissue Diagnostics provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

Europe Cancer Tissue Diagnostics Report Scope

Europe Cancer Tissue Diagnostics Regional Insights

The geographic scope of the Europe Cancer Tissue Diagnostics refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

EUROPE CANCER TISSUE DIAGNOSTICS – MARKET SEGMENTATION

By Test Type

• Immunohistochemical Tests
  • Breast Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Stomach Cancer
  • Others

• In Situ Hybridization Tests
  • Breast Cancer
  • Lung Cancer
  • Bladder Cancer
  • Others

By Country

• France
• Germany
• UK
• Italy
• Spain

Companies Mentioned

• F. Hoffmann-La Roche Ltd
• Thermo Fisher Scientific Inc.
• Bio Rad Laboratories Inc.
• Abbott
• Enzo Life Sciences, Inc.
• Agilent Technologies, Inc.
• Cancer Genetics Inc.
• Merck KGaA (Sigma-Aldrich Co. LLC)
• Danaher
• Abcam plc.